Epoprostenol sodium (prostacyclin) administered intravenously is considered the standard for assessing the ability of the pulmonary circulation to vasodilate. At present, epoprostenol sodium is an investigational drug that has limited availability. In contrast, acetylcholine, also a pulmonary vasodilator, is readily available. Therefore, we assessed the feasibility of using acetylcholine as an alternative to prostacyclin in testing for the capacity of the pulmonary vasculature to vasodilate. Twenty-three patients with primary pulmonary hypertension (mean pulmonary arterial pressure, 58.5±13.4 mm Hg) received incremental infusions of prostacyclin and acetylcholine to predetermined maximal infusion rates as part of a battery of vasodilator agents administered according to standard protocols (mean, 5.4±|1.2 agents/patient; range, 3-8 agents/patient); the administration of the different agents was timed to avoid synergistic effects. Of all the agents tested, prostacyclin and acetylcholine were most consistently effective in evoking acute pulmonary vasodilation, and both seemed to distinguish patients capable of manifesting acute pulmonary vasodilation from those who were not. However, at maximal doses set by protocol, prostacyclin generally elicited a greater vasodilator response than acetylcholine. The difference in magnitude of response may have been due to use of prescribed dosages of acetylcholine that were submaximal. In other respects, the two agents were similar, both were equally well-tolerated, and side effects were mild and resolved rapidly when the vasodilator infusions were stopped. We conclude that in the majority of patients with primary pulmonary hypertension, acetylcholine appears to be an effective and available substitute for prostacyclin in screening for pulmonary vasodilator responsiveness. (Circulation 1990;82:2018-2026 F or more than 30 years, pharmacological agents have been tested for their ability to induce pulmonary vasodilation in patients with primary (idiopathic) pulmonary hypertension (PPH). Acetylcholine, administered intravenously, was among the first agents tested in the search for safe and effective pulmonary vasodilators,'-4 but its use From the Pulmonary and Critical Care Section
was abandoned when agents that could be administered orally became available. [5] [6] [7] [8] [9] In recent years, the search for pulmonary vasodilators has intensified because of the availability of multiple systemic vasodilators10-12 that might be tailored to act as pulmonary dilators by adjusting dosage to avoid systemic hypotension and other adverse effects.12 '3 One of the newer agents is epoprostenol sodium (prostacyclin), which is currently available only for intravenous administration. '4-17 This agent has been successful in identifying responsive patients with PPH; it has been advocated as a "gold standard" that can be used safely as a predictor of whether vasodilator agents taken orally are likely to be safe and effective. '6-18 However, prostacyclin is still an investigational drug and is limited in availability.
In contrast to prostacyclin, acetylcholine, which also can only be given intravenously, is readily available. In this study, we compared the effects of acetylcholine and prostacyclin as screening agents for acute pulmonary vasodilation in patients with PPH.
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These agents were incorporated into the battery of drugs conventionally used in patients with PPH to test for acute pulmonary vasodilator responsiveness, including agents that can be taken orally for maintenance therapy. 12 Preliminary results of our comparisons between acetylcholine and prostacyclin have been presented in an abstract. 19 
Methods

Patient Population
Twenty-three of the 28 patients with PPH who were referred to our program in pulmonary vascular disease at the Hospital of the University of Pennsylvania between April 1985 and October 1988 comprised the population of this study. These represent all patients who consented to this protocol and who received prostacyclin, acetylcholine, and at least one other vasodilator agent. All of the patients had PPH as defined by the criteria of the National Institutes of Health-sponsored Patient Registry for the Characterization of Primary Pulmonary Hypertension20; before testing, each patient had undergone both clinical and laboratory evaluations, including blood serologies, chest radiography, pulmonary function testing, ventilation-perfusion lung scans or pulmonary angiography, echocardiography, and cardiac catheterization. In no instance was a coexisting illness found that could account for the pulmonary vascular disease. Each patient received prostacyclin, acetylcholine, and at least one other vasodilator agent. The protocols for this study were approved by the Committee on Studies Involving Human Beings of the Office of Research Administration of the University of Pennsylvania. Informed consent was obtained from each patient before enrollment in this study.
Hemodynamic Studies
All evaluations were performed in the Medical Intensive Care Unit of the Hospital of the University of Pennsylvania. Any agent suspected of having the potential to vasodilate the pulmonary vascular bed was discontinued at least 3 days before the vasodilator tests; all medications were withheld on the morning of the right heart catheterization. Right atrial pressure, pulmonary arterial pressure (PPA), pulmonary arterial occlusion pressure (PPAO), and cardiac output (CO) were determined by using a balloonflotation, triple-lumen, thermodilution catheter, which was advanced into the pulmonary artery through an antecubital or internal jugular vein.
Pulmonary vascular resistance (PVR) (in dynesx secondsxcentimeters-5) was calculated as the difference between mean PPA and mean PPAO divided by CO and then multiplied by 79.9. CO (in liters per minute) was determined in the supine position by using the thermodilution method in those patients who did not have clinically evident tricuspid regurgitation (18 patients). CO determinations by thermodilution method were repeated at least in triplicate to ensure reproducibility; the mean of three values, each of which differed from one another by 15% or less were used in all calculations and in the tables. In those patients who had clinical evidence of tricuspid regurgitation (five patients), CO was determined using the Fick principle. Systemic arterial pressure was determined intermittently using standard sphygmomanometry or by an automated blood pressure cuff (Dinamap 845xT, Critikon, Inc., Tampa, Fla.). Heart rate was determined from a continuous electrocardiographic recording.
Electrocardiograms and PPAS were continuously recorded at the bedside; all pressures were measured at end expiration. Before initiating the first test agent, pulsatile PPA and CO were determined repeatedly until stable baseline values (varying less than 10% over 30 minutes of observation) were obtained.
Vasodilator Protocol
After PPA and CO were stable for at least 30 minutes, vasodilator agents were administered sequentially in an order determined by increasing pharmacological half-lives. On the average, 5 Table 1 ).
Mean PVR was 1,306+598 dynes * sec. cm-5 (range, 495-2,525 dynes. sec. cm-5) in the 22 patients in whom complete data for this calculation were available.
Vasodilator Responses
The maximal percent change in PVR, mean PPA, and CO after administration of acetylcholine and prostacyclin to each patient are presented in Table 2 .
Comparisons of responses to prostacyclin and acetylcholine. The changes (percent of control) in mean PPA, CO, and calculated PVR elicited by acetylcholine and prostacyclin are shown in the panels of Figure 1 . On the average, the changes in mean PPA were similar (top panel), whereas the increase in CO and the decrease in calculated PVR were usually greater after prostacyclin (middle and bottom panels).
Comparing the ability of these agents to identify a reactive pulmonary vascular bed, we found that prostacyclin elicited a vasodilator response (decrease in PVR .30%) in seven of the 23 patients, whereas acetylcholine elicited a vasodilator response in five patients, four of whom also responded to prostacyclin. In three patients, prostacyclin elicited a vasodilator response, whereas acetylcholine did not. Conversely, in only one patient, acetylcholine elicited a response, whereas prostacyclin did not. All four of the patients who responded to both prostacyclin and acetylcholine also responded to at least one of the standard vasodilator agents.
Because of our concern that the maximal protocol infusion rates of both prostacyclin and acetylcholine may have been, in some patients, insufficient to evoke hemodynamic changes satisfying the criteria for vasodilator responsiveness, we analyzed the responses in those patients in whom the maximal protocol infusion rates were achieved, that is, those in whom the infusion rates were not limited by side effects (Table 2) . Eighteen patients were able to reach the maximum protocol-set acetylcholine infusion rate of 10 mg/min, whereas only four patients were able to tolerate the maximum protocol-set prostacyclin infusion rate of 12 ng/kg/min. Of the four patients who reached the preset maximum protocol infusion rates for prostacyclin, three were responders; the fourth (patient 3) had no response and, at this maximal protocol infusion dose, appeared to be beginning to experience adverse systemic hemodynamic effects, that is, decreased CO. Therefore, it does not appear that a protocol allowing higher prostacyclin infusion rates would have identified additional vasodilator responsive patients.
Of the 18 patients who reached the maximum protocol-set infusion rate for acetylcholine, only five were responders. One of the prostacyclin responders Tables 1 and 2 . Responders demonstrated a decrease in pulmonary vascular resistance of 30% or more after administration of a vasodilator agent (see text).
*Acetylcholine was not one of the agents.
tResponse to at least one agent.
(patient 20) failed to respond at the maximum protocol infusion rate for acetylcholine; the possibility remains that a higher infusion rate of acetylcholine would have identified this patient as a responder. The possibility also remains that several other patients who received the maximal acetylcholine infusion rate allowed by protocol (including four of the six patients in whom prostacyclin produced at least a 20% greater decrease in PVR than did acetylcholine) might have become "responders" if higher acetylcholine doses had been used. Prostacyclin and acetylcholine, compared with standard vasodilator agents. Tables 3 and 4 compare prostacyclin and acetylcholine with respect to their ability to identify acute responsiveness to other vasodilator agents that have therapeutic potential (many of which can be given orally). In six of the 23 patients, one or more of the standard vasodilator agents (excluding prostacyclin and acetylcholine) elicited a favorable hemodynamic response; that is, the calculated PVR decreased by more than 30%. In three of these, multiple agents exhibited favorable responses (patients 11 and 12, three agents; patient 6, two agents). Prostacyclin and acetylcholine both identified all three of these patients. Prostacyclin identified two of the patients who responded acutely to only one standard vasodilator agent (patients 2 and 23), whereas acetylcholine only identified one of these (patient 23). The final patient (patient 5) only re- sponded to the nitroprusside infusion; he exhibited a 16% decrease in PVR at the maximum acetylcholine protocol dose of 10 mg/min; prostacyclin had been discontinued at 6 ng/kg/min secondary to headache, at that dose PVR was reduced over 23% from baseline.
We then compared the pulmonary vasodilator responses to prostacyclin and acetylcholine with those of the calcium channel blockers for two reasons: 1) Calcium channel blockers have become widely accepted as the most effective oral pulmonary vasodilators. 2) No patient in this study responded to other standard vasodilator agents without also responding to a calcium channel blocker. Figure 2 presents the percent change in PVR elicited by either of the calcium channel blockers with those observed after prostacyclin (top panel) and acetylcholine (bottom panel). In those patients who manifested a response to a calcium channel blocker (patients 2, 6, 11, 12, and 23), prostacyclin elicited similar decrements in PVR in all five patients, and acetylcholine produced responses of similar magnitude in four of the five patients (all except for patient 2).
Patient tolerance of prostacyclin and acetylcholine.
Both the prostacyclin and acetylcholine infusions were well tolerated. At higher dosages, prostacyclin frequently caused headaches or nausea, both of which resolved rapidly after discontinuation of prostacyclin infusions. In one instance, the prostacyclin infusion was associated with the development of symptomatic bradycardia and hypotension; these manifestations also resolved rapidly when the prostacyclin infusion was stopped. Similarly, acetylcholine infusions were associated with asymptomatic bradycardia or headache in two patients; these also resolved rapidly when the acetylcholine infusion was stopped.
Discussion
Vasodilator Therapy in Primary Pulmonary Hypertension
During the last few years, data have been accumulating that suggest that many patients with PPH who respond favorably to the acute administration of vasodilator agents can be improved by the chronic administration of one or more vasodilator agents.16,22,23 However, it is also evident that vasodilators are not without risk in these patients, that is, systemic hypotension, worsening of right heart failure, exacerbation of pulmonary hypertension, or systemic arterial oxygen desaturation.13 These adverse effects are particularly troublesome and may even result in death if the vasodilator is not cleared rapidly from the body and if the pharmacological effects are not rapidly reversible. Because of the possibility of severe adverse effects, as well as the interest in determining if the pulmonary circulation of the patient with PPH can vasodilate, increasing attention has focused on the identification of screening agents that can be given safely for the acute assessment of pulmonary vasoreactivity. to screen for vasodilator responsiveness, no oral analogue of prostacyclin is as yet available, prostacyclin has not yet been approved by the Food and Drug Administration for use as a pulmonary vasodilator, and its availability is currently limited to use as an investigational drug.
In this study, we found that seven of 23 patients (30.4%) had at least a 30% decrease in PVR after prostacyclin. This response rate is less than that reported in several previous studies, in which more than 50% of the patients exhibited responses of this magnitude.14-18 This difference in response rate may be due, in part, to our use of supplemental oxygen administration to eliminate the possibility of hypoxic vasoconstriction that could be reversed by the prostacyclin. It is our standard practice to measure arterial oxygen saturation by pulse oximetry, at rest and during maximal exertion, in all patients with PPH. Any patient who demonstrates arterial desaturation, either at rest or during exertion, is treated with sufficient supplemental oxygen, usually administered by nasal cannulas, to maintain arterial oxygen saturation above 90% at all times. Eight of the study patients were receiving supplemental oxygen at the time of vasodilator administration; only one of these patients met our criteria for vasodilator response upon prostacyclin administration. Since oxygen and prostacyclin have been shown to be at least additive as pulmonary vasodilators,26 this use of supplemental oxygen to eliminate the hypoxic stimulus may have reduced resting pulmonary vascular tone in our patients, thereby diminishing the degree of acute vasodilation induced by the vasodilator agents. This effect has also been noted when calcium channel blockers and oxygen are administered concurrently in patients with pulmonary hypertension.27 Acetylcholine Acetylcholine is also suitable as a screening agent for pulmonary vasodilating capability. It has a short pharmacological half-life so that with proper dosage its vasodilator effects can be virtually confined to the pulmonary circulation, and it is well tolerated during acute administration. Unlike prostacyclin, acetylcholine is currently readily available, although it has not been approved for use as a pulmonary vasodilator. However, there is no analogue available for longterm oral administration.
Comparing Prostacyclin With Acetylcholine
The pulmonary vasodilatory responses to prostacyclin and to acetylcholine observed in the present study suggest that, whereas both agents are successful in identifying patients who respond acutely to other vasodilators, the vasodilator responses elicited by prostacyclin are greater in magnitude. This trend may in part be due to the use of submaximal doses of acetylcholine; for both the prostacyclin and acetylcholine infusions, we followed protocols that included arbitrary protocol-set limits for the maximum infusion rates of the agent, 12 ng/kg/min in the case of prostacyclin and 10 mg/min in the case of acetylcholine. However, whereas only four patients could tolerate the preset maximum infusion rate for prostacyclin without having to have the infusion terminated due to systemic hypotension or other side effects, 18 patients were able to tolerate the present maximum infusion rate for acetylcholine. This difference raises the possibility that higher infusion rates of acetylcholine would have been tolerated and might have elicited greater vasodilator effects. It should be emphasized that in only one patient (patient 7) were the effects of the two agents strikingly divergent and that this patient did not respond to any other agent.
Prostacyclin and Acetylcholine as Predictors of Vasodilator Responses to Standard Vasodilator Agents
In this study, as in our previous studies7,21 of vasodilator responses in primary pulmonary hypertension, individual patients differed considerably in their responses to the different vasodilator agents. Moreover, any particular agent elicited different responses in different patients. Despite this variability among vasodilator agents, both prostacyclin and acetylcholine were able to predict which patients would demonstrate acute pulmonary vasodilation in response to the calcium channel blockers, currently the most commonly used pulmonary vasodilators available for long-term oral therapy'2,23; prostacyclin identified all five of the patients who exhibited acute vasodilator responses to the calcium channel blockers, whereas acetylcholine elicited a vasodilator response in four of these patients. No patient in this study manifested an acute vasodilator response to other standard vasodilator agents without also responding to the calcium channel blockers. However, because of their long plasma half-lives, the calcium channel blockers are not suitable agents for screening for acute pulmonary vascular responsiveness.
On the basis of this study, we conclude that in patients with PPH prostacyclin appears to be the most consistent of the available pulmonary vasodilators and that acetylcholine appears to be useful as 
